Topics

Articles

The industry is far from ready when it comes to collecting, aggregating, cleansing and disclosing data about regulated financial transactions with doctors and hospitals

Aggregate Spend Laws: Here Comes the Sun

First-ever study of the impact of REMS on supply chains finds that collaboration is a critical requirement

How REMS Affect Pharmaceutical Distribution Processes and Partners

Google Prepares for a Possible $500-Million Penalty for Illegal Online Pharmacy Advertising, Says WSJ

FDA's Social Media Enforcement:  Emerging Rules of Engagement

Caseload reinforces concerns over illegal trade and distribution of pharmaceuticals

FDA Opened 72 New Counterfeit Cases in 2010--a New Record

Industry and regulators are taking steps to revolutionize the basic regulatory function of collecting and analyzing adverse medical events

Adverse Event Reporting: At the Front Lines of Drug Safety

More pieces for industry-wide track-and-trace are falling into place, but there’s no rush to authenticate products

2010 Product Security Report

Senator Michael Bennet wants better FDA oversight of drug supply chain and material sourcing, as survey shows that 36% of Americans likely to vote have heard of unsafe ingredients

Consumer Survey Highlighting Drug-Safety Worries Accompanies Introduction of

A Process-Based Assessment (PBA) is the first step to analyzing reporting needs

A Process-Based Approach To Aggregate Spend

REMS programs need to address stakeholder usability

Legal and Regulatory